FDA Issues Boxed Warning for CYP2C19-Linked Poor Metabolism of Plavix

The boxed warning for Plavix's label alerts doctors that genetic tests are available to establish patients' CYP2C19 status. However, the FDA leaves it up to physicians to decide whether to wait for genetic testing results or put patients on an alternative treatment.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.